Search the Newsreel

OMA/B: EBITDA margin hit 75.2% as commercial and cargo revenues surged, supporting double-digit net income growth

OMA/B (Grupo Aeroportuario del Centro Norte SAB de CV Class B) reported modest passenger traffic growth alongside significant increases in commercial and cargo revenues. This led to an expanded EBITDA margin of 75.2% and a 10.2% rise in net income year-over-year. The company continued …

Grupo Aeroportuario del Centro Norte Q2 Earnings Call Highlights

Grupo Aeroportuario del Centro Norte (OMAB) reported its Q2 2026 results, showing a 0.4% increase in passenger traffic to 7.2 million, driven by domestic growth despite an international decline. The company achieved a 6.2% rise in adjusted EBITDA to MXN 2.7 billion and a …

Chemomab Therapeutics Ltd (CMMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. …

Healthcare of Ontario Pension Plan Trust Fund Acquires 5,800 Shares of Grupo Aeroportuario Del Pacifico, S.A. de C.V. $PAC

Grupo Aeroportuario del Centro Norte (NASDAQ:OMAB) Posts Earnings Results, Beats Expectations By $0.05 EPS

OMAB|Grupo Aeroportuario del Centro Norte SAB de CV|Price:106.310|Chg%:-1.960

This article provides a comprehensive stock analysis of Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) from TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation, ranking it 2nd in the Transport Infrastructure industry. The analysis also notes high …

Grupo Aeroportuario del Centro Norte SAB de CV

The article provides a revenue breakdown page for Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) on TradingKey. It indicates that relevant data for business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays general …

Chemomab Therapeutics Ltd (CMMB) Institutional Confidence

This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with …

Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) Dividends & Stock Splits: Historical Payouts and Event Timeline — TradingKey

This article provides detailed historical dividend and stock split information for Grupo Aeroportuario del Centro Norte SAB de CV (OMAB), listed on TradingKey. It includes a table with dividend dates, types, amounts, record dates, payment dates, and ex-dividend dates, showing payouts totalling $868.42 million …

Chemomab Therapeutics Ltd

This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page …

Chemomab Therapeutics Ltd (CMMB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Chemomab Therapeutics Ltd (CMMB). It notes that no dividends have been distributed over the past five years, but lists several stock splits, including a 4:1 merger in August 2025 and multiple 16:1 mergers in …

Chemomab Therapeutics Ltd (CMMB) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Chemomab Therapeutics Ltd (CMMB), noting key financial metrics. As of the close on July 24th, CMMB had a market cap of $39.17 million and a P/E TTM of 7.81. However, specific P/E, P/B, and P/CF data …

OMAB Balance Sheet - Grupo Aeroportuario del Centro Norte SAB de CV

This article presents the quarterly and annual balance sheets for Grupo Aeroportuario del Centro Norte SAB de CV (OMAB), allowing investors to evaluate the company's financial health, analyze fundamentals, and calculate key ratios. It includes detailed financial data for assets, liabilities, and shareholders' equity …

Renaissance Technologies LLC Lowers Position in Grupo Aeroportuario Del Pacifico, S.A. de C.V. $PAC

Chemomab Therapeutics Ltd (CMMB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Chemomab Therapeutics Ltd (CMMB), focusing on volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return Best/Worst Daily Return, Sharpe Ratio, Skewness, Realised Volatility, Standardised True Range, Downside …

Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB

This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.

Price to earnings forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides the "Price to earnings forward" value for AgomAb Therapeutics NV (NASDAQ: AGMB). It shows that for the specified period, the value is listed as "No trades." The information is presented within a financial data context.

CMMB|Chemomab Therapeutics Ltd|Price:1.800|Chg%:+0.050

This article provides a stock score and comprehensive analysis of Chemomab Therapeutics Ltd (CMMB) from TradingKey. It details how TradingKey generates its stock scores across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. The article states that …

Empirical Finance LLC Makes New $7.69 Million Investment in Grupo Aeroportuario del Sureste, S.A. de C.V. $ASR

AgomAb Therapeutics NV Revenue Breakdown – NASDAQ:AGMB

This article displays the revenue breakdown for AgomAb Therapeutics NV, trading under the NASDAQ symbol AGMB. It provides a financial overview of the company, focusing on fundamentals, statements, statistics, dividends, earnings, and segment performance. The content includes links to various financial data and tools …

Grupo Aeroportuario del Centro Norte SAB de CV Class B (OMAB) Q4 2025 Earnings Report - Results, Call & Slides

Grupo Aeroportuario del Centro Norte SAB de CV (OMAB) reported its Q4 2025 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of $3.15 against a consensus of $3.87, and actual revenue of $4.11 billion compared to an expected $4.45 …

Grupo Aeroportuario del Sureste: Q2 Earnings Snapshot

B.Riley initiates Agomab Therapeutics stock with buy rating

B.Riley has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a "buy" rating and a price target of $34.00, suggesting a nearly 200% upside from its current trading price of $11.60. The firm highlights Agomab's focus on developing organ-restricted small-molecule inhibitors for fibrosis, particularly in …

Militia Capital Management LLC Purchases New Position in Grupo Aeroportuario del Centro Norte S.A.B. de C.V. $OMAB

OMAB Stock 12‑Month Price Target Cut to $121.7, Implies 16% Upside

The average 12-month price target for Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (OMAB) stock has been trimmed to $121.7 from $122.47 by 16 analysts, with forecasts ranging from $97.75 to $150. Based on the closing price of July 22, this new target …

Are options traders betting on a big move in Grupo Aeroportuario stock?

This article analyzes unusual options activity in Grupo Aeroportuario del Sureste (ASR) to determine if institutional investors are predicting a significant price movement. It highlights key options trades, including their sentiment (bullish/bearish), expiration dates, and strike prices, to infer potential market expectations for the …

OMA (NASDAQ: OMAB) completes Ps.3.0B Mexican long-term note issue

Grupo Aeroportuario del Centro Norte (OMA), operating under the NASDAQ symbol OMAB, has announced the completion of a Ps.3.0 billion long-term note issuance in the Mexican market. OMA manages 13 international airports across nine states in central and northern Mexico and is part of …

Chemomab Therapeutics (CMMB) Q4 2025 earnings summary

Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced …

Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to FDA alignment for a single pivotal Phase …

OMA prices MXN 3 billion long-term bond offering in Mexico

Grupo Aeroportuario del Centro Norte (OMA) has successfully priced a MXN 3 billion long-term bond offering in the Mexican market, split into 3-year and 7-year tranches. The offering was significantly oversubscribed, with an order book reaching 3.2 times the offered amount. Proceeds from the …

Grupo Aeroportuario del Centro Norte (NASDAQ: OMAB) prices Ps.3.0B in top-rated notes

Grupo Aeroportuario del Centro Norte (OMA) has successfully issued Ps.3.0 billion (approximately $170 million USD) in long-term notes in the Mexican market, attracting significant demand from institutional investors. The notes received the highest national-scale ratings from Fitch and Moody's Local, both with stable outlooks. …

HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan

HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which includes contingent value rights for current …

Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?

AgomAb Therapeutics: High Risk, High Reward Stock (NASDAQ:AGMB)

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings